Inscrição na biblioteca: Guest
Portal Digital Begell Biblioteca digital da Begell eBooks Diários Referências e Anais Coleções de pesquisa
Forum on Immunopathological Diseases and Therapeutics
SJR: 0.164 SNIP: 0.041 CiteScore™: 0.18

ISSN Imprimir: 2151-8017
ISSN On-line: 2151-8025

Archives: Volume 1, 2010 to Volume 7, 2016

Forum on Immunopathological Diseases and Therapeutics

DOI: 10.1615/ForumImmunDisTher.2015014118
pages 195-214

Druggable Targets in Pancreatic Adenocarcinoma

Stefania Nobili
Department of Health Sciences, University of Florence, Firenze, Italy
Renato Tassi
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Ida Landini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy
Gabriele Perrone
Department of Health Sciences, University of Florence, Firenze, Italy
Cristina Napoli
Department of Health Sciences, University of Florence, Firenze, Italy
Enrico Mini
Department of Experimental and Clinical Medicine, University of Florence, Firenze, Italy

RESUMO

Pancreatic ductal adenocarcinoma (PDAC) is a leading cause of cancer-related death worldwide. It is often diagnosed at an advanced or metastatic stage and results of the approved systemic therapies are discouraging, making PDAC one of most lethal cancers in Western countries. In recent years, a better comprehension of PDAC unique biology has disclosed new potential targets for therapeutic interventions. Meanwhile, the development of conjugated agents, small molecules, antibodies, and immunoagents has opened therapeutic opportunities for drugs able to exert therapeutic effects on druggable targets of PDAC biology. Despite some failures, this approach is bringing meaningful results from bench to bedside, and more efficacious therapeutic opportunities may become available for PDAC treatment. In this review, we discuss the main hallmarks of PDAC biology as its microenvironment, cancer-driving proliferative pathways, growth suppression loops, and how PDAC evades immune system surveillance, as well as molecular aspects of each feature. The main preclinical and clinical results of each targeted intervention are also presented considering its biological rationale. Ongoing clinical trials provide evidence of the effectiveness of this approach and promising results in the treatment of PDAC.


Articles with similar content:

Cytogenetic, Molecular, and Translational Applications in Pancreatic Ductal Adenocarcinoma: Current Evidence and Future Concepts
Critical Reviews™ in Oncogenesis, Vol.24, 2019, issue 2
Rama Rao Malla, Seema Kumari
Victory and Defeat in the Induction of a Therapeutic Response through Vaccine Therapy for Human and Canine Brain Tumors: A Review of the State of the Art
Critical Reviews™ in Immunology, Vol.34, 2014, issue 5
Nate N. Waldron , G Elizabeth Pluhar, Rob Shaver, Brian M. Andersen, Michael R. Olin, Christopher L. Moertel
New Prospectives of Prostate Cancer Gene Therapy: Molecular Targets and Animal Models
Critical Reviews™ in Eukaryotic Gene Expression, Vol.11, 2001, issue 1-3
Chia-Ling Hsieh, Leland W. K. Chung
Prostate Cancer and Parasitism of the Bone Hematopoietic Stem Cell Niche
Critical Reviews™ in Eukaryotic Gene Expression, Vol.22, 2012, issue 2
Kenneth J. Pienta, Chunyan Yu, Yusuke Shiozawa, Evan T. Keller, Laurie K. McCauley, Russell S. Taichman
Toward Prediction of Immune Mechanisms and Design of Immunotherapies in Melanoma
Critical Reviews™ in Biomedical Engineering, Vol.40, 2012, issue 4
Frank O. Nestle, Louise Saul, Sophia N. Karagiannis, Sophia Tsoka, Debra H. Josephs, Chrysanthi Ainali, Panagiotis Karagiannis